All News
Filter News
Found 88 articles
-
The company indicated that its timeline for an accelerated approval request for its own Alzheimer’s drug, donanemab, was no longer on schedule for the first quarter after the CMS draft guidance.
-
Lilly Reports Solid Fourth-Quarter and Full-Year 2021 Financial Results, Recent Late-Stage Pipeline Successes Set Up Next Wave of Innovative Medicines for Patients
2/3/2022
Eli Lilly and Company announced financial results for the fourth quarter and full year of 2021.
-
Evotec entered into a drug discovery collaboration for metabolic diseases with Eli Lilly, focusing on kidney disease and diabetes.
-
The Danish pharma giant is partnering with EraCal Therapeutics, to develop new obesity-related drug targets.
-
U.K.-based Clarivate Plc has identified seven late-stage assets or recently-approved drugs that could hit the billion-dollar per year mark within five years.
-
Viking Therapeutics Announces Initiation of Phase 1 Clinical Trial of VK2735, Company's Lead Dual GLP-1/GIP Receptor Agonist
1/10/2022
Viking Therapeutics, Inc. announced the initiation of a Phase 1 single ascending dose and multiple ascending dose clinical trial of VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors.
-
Eli Lilly and Company’s projections for next year exceed Wall Street projections for the company, predicting 2022 revenue of $27.8 billion to $28.3 billion.
-
Lilly Highlights Innovation-based Growth Strategy and Pipeline Developments; Announces 2022 Financial Guidance at Investment Community Meeting
12/15/2021
Eli Lilly and Company (NYSE: LLY) is providing extensive updates across its research and development (R&D) programs to highlight the company's strong pipeline and potential for future growth.
-
Viking Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
11/3/2021
Viking Therapeutics, Inc. today announced its financial results for the third quarter and nine months ended September 30, 2021, and provided an update on its clinical pipeline and other corporate developments.
-
Viking Therapeutics Presents Preclinical Data on Novel Dual GLP-1/GIP Agonists at ObesityWeek® 2021
11/1/2021
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced the presentation of preclinical data from a series of internally developed dual agonists of the glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors at ObesityWeek® 2021.
-
Lilly to Participate in Bernstein's Second Annual Operational Decisions Conference
11/1/2021
Eli Lilly and Company (NYSE: LLY) will participate in Bernstein's Second Annual Operational Decisions Conference on Thursday, Nov. 4 , 2021.
-
Lilly Reports Robust Third-Quarter 2021 Financial Results as Pipeline Success Strengthens Future Growth Potential
10/26/2021
Eli Lilly and Company announced financial results for the third quarter of 2021.
-
SURPASS-4 is part of the Phase III trial evaluating tirzepatide as a possible treatment for type 2 diabetes.
-
Tirzepatide results published in The Lancet show superior A1C and body weight reductions compared to insulin glargine in adults with type 2 diabetes with increased cardiovascular risk
10/19/2021
Adults with type 2 diabetes with increased cardiovascular risk experienced superior A1C and body weight reductions from baseline across all three doses of tirzepatide compared to titrated insulin glargine in detailed results from Eli Lilly and Company's SURPASS-4 clinical trial, which were published in The Lancet.
-
Indianapolis-based Eli Lilly presented data from two tirzepatide sub-studies at the 57th European Association for the Study of Diabetes (EASD) Annual Meeting.
-
Lilly's tirzepatide led to greater improvements in liver fat content compared to insulin degludec in adults with type 2 diabetes in SURPASS-3 MRI sub-study
9/30/2021
Tirzepatide led to greater improvements in liver fat content and abdominal adipose tissue compared to titrated insulin degludec in adults with type 2 diabetes in an MRI sub-study of Eli Lilly and Company's phase 3 SURPASS-3 clinical trial.1 The results were presented at the 57th European Association for the Study of Diabetes Annual Meeting in an EASD-sponsored symposium.
-
Lilly's tirzepatide led to greater time in range compared to insulin degludec in adults with type 2 diabetes in SURPASS-3 CGM sub-study
9/30/2021
All three tirzepatide doses led to more time in tight target range, improved glycemic variability and numerically less time in hypoglycemia compared to titrated insulin degludec in adults with type 2 diabetes in a continuous glucose monitoring sub-study1 of Eli Lilly and Company's phase 3 SURPASS-3 clinical trial.
-
Lilly Announces Leadership Changes and Formation of Neuroscience and Immunology Business Units
8/17/2021
Eli Lilly and Company announced executive leadership changes and the creation of neuroscience and immunology business units.
-
Lilly Delivers Strong Second-Quarter 2021 Financial Results, Updates 2021 Financial Guidance
8/3/2021
"We delivered strong performance this quarter, with volume-driven growth across our core business and most major geographies.
-
Clinical Catch-Up: June 28-July 2
7/6/2021
It was another busy week for clinical trial news ahead of the July 4 holiday in the U.S. Here’s a look.